DBV Technologies S.A. (DBVT)
Nasdaq · Healthcare · Biotechnology
$10.44−1.04%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $656M
- 52-week range
- $10.23 – $26.19
- 52-week change
- −25.91%
- EPS (trailing)
- −$3.50
- Analyst rating
- 1.7 Buy
- Next earnings
- Oct 28, 2026
Fiscal year to Dec 2025
- Revenue
- $5.6M (+35.77%)
- Net income
- −$147M
- Operating margin
- −2609.3%
- Diluted EPS
- −$1.05
- Free cash flow
- −$122M
From the company’s annual report on SEC EDGAR.
About DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Headquarters: Châtillon, France · 170 employees · dbv-technologies.com